Dendritic cells (DCs) sense the microenvironment through several types of receptors recognizing pathogen-associated molecular patterns. In particular, C-type lectins, expressed by distinct subsets of DCs, recognize and internalize specific carbohydrate antigen in a Ca 2+ -dependent manner. Targeting of these receptors is becoming an efficient strategy of delivering antigens in DC-based anticancer immunotherapy. Here we investigated the role of the macrophage galactose type C-lectin receptor (MGL), expressed by immature DCs (iDCs), as a molecular target for α-N-acetylgalactosamine (GalNAc or Tn)-carrying tumor-associated antigens to improve DC performance. MGL expressed by ex vivo-generated iDCs from healthy donors was engaged by a 60-mer MUC1 9Tn -glycopeptide as a Tn-carrying tumor-associated antigen, and an anti-MGL antibody, as a specific MGL binder. We demonstrated that MGL engagement induced homotrimers and homodimers, triggering the phosphorylation of extracellular signal-regulated kinase 1,2 (ERK1,2) and nuclear factor-κB activation. Analysis of DC phenotype and function demonstrated that MGL engagement improved DC performance as antigen-presenting cells, promoting the upregulation of maturation markers, a decrease in phagocytosis, an enhancement of motility, and most importantly an increase in antigen-specific CD8 + T-cell activation. These results demonstrate that the targeting of MGL receptor on human DCs has an adjuvant effect and that this strategy can be used to design novel anticancer vaccines.
Introduction
Dendritic cells (DCs), as professional antigen-presenting cells (APCs), sense the microenvironment through different types of [2] . DCs are equipped with several highly specialized receptors including C-type lectin receptors (CLRs) and Tolllike receptors (TLRs). In contrast to TLRs, CLRs recognize and internalize specific carbohydrate antigens in Ca 2+ -dependent manner [3] , thus, influencing the outcome of the immune response. The most important molecules from the CLR family include macrophage galactose type C-lectin (MGL), dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN), the mannose receptor, DEC205, and Dectin-1. These receptors are able to trigger distinct signaling pathways that modulate DC functions through the expression of specific molecules and cytokines, determining the polarization of T cells [4] . These properties make this C-type lectin family an optimal tool for DC targeting in cancer vaccination. Human MGL (hMGL) is a type II C-type lectin, expressed in vitro by macrophages and monocyte derived DCs and in vivo by DCs of skin and lymph nodes [5, 6] . Its carbohydrate recognition domains contain a QPD sequence that is responsible for recognition of α-or β-N-acetylgalactosamine (GalNAc, Tn) residues of N-and O-glycans carried by glycoproteins and/or glycosphingolipids [7] . In mice, there are two homologs of hMGL, MGL1 and MGL2 [8] , expressed by dermal DCs and alternatively activated macrophages [5, 9] . MGL1 is highly specific for Lewis X and Lewis A structures, while MGL2, similar to the hMGL, recognizes N-GalNAc and galactose, including O-linked Tn-antigen, TFantigen, and core 2 structures [10] . hMGL is equipped with a partial dileucine zipper and with YENF internalization motifs [11] . This receptor is involved in the recognition of a large plethora of pathogens by DCs [12] [13] [14] [15] and in the maintenance of T-cell homeostasis [16] . Moreover, in vivo, MGL appears to play a crucial role in close proximity of the endothelial structures of lymph nodes and thymus, where iDCs are hampered in their migration activity until maturation [6] . In cancer, MGL has been described to enable DCs to sense glycosylation [17] and to selectively recognize tumor-associated glycoproteins [18] . The Tn-MUC1 glycoform represents one of the tumor-associated antigens (TAAs) studied as an MGL ligand. MUC1 is a transmembrane epithelial mucin made up of a repeated stretch of 20 amino acid tandem repeated (TR) sequence with several sites of attachment for O-linked glycans [19] . In tumors, MUC1 is overexpressed, aberrantly glycosylated, and shed in the tissue microenvironment. MUC1-TAAs carry shortened O-glycans such as GalNAcα1-O-Ser/Thr (Tn) or Galβ1-3GalNAcα1-O-Ser/Thr (T) which may be sialylated [20] . We previously demonstrated that DCs were able to bind to MUC1 9Tn glycopeptide (3TRs corresponding to 60 amino acids carrying nine Tn moles) through MGL and this interaction favored the Tn-antigen processing in human histocompatibility leukocyte Ag (HLA) class I and II compartments [18] , suggesting its potential application in ex vivo DC-based vaccination.
In this work, we have investigated the effects of MGL targeting on the phenotype and function of ex vivo-generated DC populations, in order to understand whether this receptor could be used as molecular target to activate a potent CD8 + T-cell activation for cell therapy. The ligands chosen for this study were the MUC1 9Tn peptide as a model of a Tn-carrying TAA and an anti-MGL antibody as a specific MGL binder. The results demonstrate that MGL activated by both ligands oligomerizes and subsequently activates the extracellular signal-regulated kinase 1,2 (ERK1,2) and nuclear factor-κB (NF-κB) pathways and induces phenotypic and functional DC maturation that then enables the DCs to initiate a strong CD8 + T-cell immune response.
Results

MGL oligomerized and activated the ERK1,2 and NF-κB pathways
Immunofluorescence experiments were conducted to visualize MGL expression changes following receptor engagement. MGL was heterogeneously distributed in iDC population and its localization appeared diffuse on the plasma membrane ( Fig. 1A-before) . After the addition of MUC1 9Tn peptide to iDCs, MGL clustered and its distribution became spotted ( Fig. 1A-after) . To characterize the receptor complex generated after engagement, MGL clusters were immunoprecipitated and analyzed by western blotting in reducing and non-reducing conditions (Fig. 1B) . Two different MGL ligands were used for oligomerization studies: MUC1 9Tn as natural ligand and an anti-hMGL monoclonal antibody (MoAb) as specific MGL binder. When the glycopeptide was added to iDCs, MGL clustered as homotrimers and homodimers. In absence of β-mercaptoethanol, two bands corresponding to ∼120 kDa (trimers) and ∼80 kDa (dimers) were found, while a unique band corresponding to MGL monomer (∼40 kDa) was observed in reducing condition (Fig. 1B , on the left). Similar results were obtained when the anti-MGL antibody was used (Fig. 1B , on the right). After MGL engagement and crosslinking, two bands appeared at ∼420 kDa and ∼230 kDa, corresponding to immunocomplexes containing three and two MGL molecules. In reducing condition, two bands corresponding to MGL monomers and MoAb fragments were detected.
Receptor clustering is usually associated with the activation of intracellular signaling. In order to investigate whether MGL engagement triggers DC intracellular pathways, we analyzed the tyrosine phosphorylation cascades induced by both ligands at different time points. DC lysates were probed with an antipTyrosine antibody in western blotting analysis (Fig. 1C) . iDCs and iDCs treated with IgG 1 antibody (IgG 1 -DCs) were used as negative controls. Results indicate that both MUC1 9Tn and the anti-MGL MoAb induced phosphorylation of proteins with an apparent molecular weight ranging between 42 and 44 kDa, suggesting that ERK1,2 could be an optimal candidate substrate protein. When the samples were analyzed with a specific anti-pERK1,2 antibody, we observed that MGL engagement promoted the phosphorylation of ERK1,2. MUC1 9Tn appeared to trigger a stronger signal compared with the antibody: bands were visible at 5 min and disappeared after 60 min. The anti-MGL antibody activated a weak phosphorylation signal that was detectable from 5 min, increased becoming more intense at 15 min, and turned off at 60 min.
DC signaling through pattern-recognition receptors is frequently related to the NF-κB pathway [21] . The classical shown. Samples were run in 4-12% or 3-8% SDS-PAGE gels and were analyzed in reducing and nonreducing conditions. (C) Western blotting of DC lysates alone or after the addition of MUC1 9Tn peptide (left), anti-MGL, and IgG 1 antibodies (right). Samples were analyzed for tyrosine phosphorylation (pTyr), pERK1,2 (42-44 kDa), and for the presence of p50/p105 molecules at different time points. α-tubulin was used as a loading control. Proteins were resolved in 10% SDS-PAGE gel. These results are representative of one donor out of three.
NF-κB signal is dependent on the production of p50-activated form derived from the cleavage of the inactive p105 molecule [22] . Results indicated that MGL engagement by both ligands induced NF-κB activation with a similar pattern; in fact p50 is detectable at 5 min and is maintained after 120 min (Fig. 1C) .
DCs matured after MGL activation
Due to the opposite role of ERK1,2 and NF-κB signaling on DC maturation [23, 24] , we next evaluated the effects of MGL activation on phenotype and functions of DCs. We studied the expression of several DC markers after MGL binding, comparing the results with those obtained with iDCs or IgG 1 -DCs (Fig. 2 ). DCs matured with interleukin (IL)-1β, IL-6, tumor necrosis factor-α (TNF-α), and prostaglandin E 2 were used as positive control. DCs derived from six healthy donors were characterized for the expression of HLAII-DR, HLAI, CD86, CD83, CD40, CCR7, intercellular adhesion molecule (ICAM-1), CD11c, and CD1a molecules. After MGL engagement, DCs were left overnight at 37
• C to allow phenotype marker modulation. Results indicated that both MGL ligands induced DC maturation, although at different extent. The glycoimmunogen MUC1 9Tn modified DC phenotype, significantly increasing the expression of HLAII-DR, CD83, and CD40 molecules compared with that of iDCs. The average values of mean fluorescence intensity (MFI) obtained for CCR7, CD11c, and CD1a highlighted a trend in the upregulation of these markers, although these modifications were not statistically significant. The anti-MGL antibody promoted a significant upregulation of HLAII-DR, CD86, CD83, CCR7, and CD40 compared with IgG 1 -DCs, while the other DC markers appeared unmodified.
MGL engagement enhanced DC motility and reduced DC endocytosis
iDCs display an enhanced ability to capture and process pathogens, while showing a strongly reduced motility [25] . The exposure to maturation stimuli induces functional changes including down regulation of endocytic capacity and increased migration ability enabling DCs to move to lymph nodes where they present antigen to T cells. Thus, the endocytic capacity of DCs treated with MUC1 9Tn peptide (MUC1 9Tn -DCs) and with the anti-MGL antibody (a-MGL-DCs) was evaluated by fluorescein isothiocyanate (FITC)-dextran uptake and analyzed by flow cytometry (Fig. 3A) . Both ligands induced a reduction in endocytosis: this decrease corresponded to 38% when the glycopeptide was used for MGL activation (iDCs versus MUC1 9Tn -DCs: 15.4 versus 9.6) and to 56% with the antibody (IgG 1 -DCs versus a-MGL-DCs: 14.5 versus 6.4).
Moreover, MGL engagement enhanced migratory capacity of DCs, in fact as expected by the upregulation of CCR7 induced by the anti-MGL antibody and in a less pronounced manner by MUC1 9Tn , a discrete DC population acquired the capacity to migrate toward CCL19 (16 ± 3% for the antibody; 9 ± 4% for MUC1 9Tn peptide; Fig. 3B ). • C overnight before analysis. iDCs and mDCs (IL-1β, IL-6, TNF-α, and PGE 2 ) were used as negative and positive controls, while IgG 1 represents the isotype control of the anti-MGL antibody. The bars correspond to the average MFI values among six donors. Statistical significance was determined by the Student's paired t-test.
MGL activation decreased IL-10 production of DCs
IL-12 and IL-10 are two cytokines, produced by DCs, involved in the regulation and balancing of the immune response, respectively, representing two important parameters to understand the type of immune response evoked [26] . We evaluated the percentage of IL-12 and IL-10 produced by MGL-engaged DCs by intracellular staining (Fig. 3C ). DCs treated with the anti-MGL antibody showed a percentage of IL-12 producing cells significantly higher compared with IL-10 + cells (p < 0.05), thus showing a shift in the IL12/IL10 balance toward a Th1 polarization, as observed in mature DCs (mDCs) (p < 0.01). Such shift was not detectable in the other experimental conditions.
MGL-activated DCs induced allogeneic T-cell proliferation
In order to understand the effects of MGL-induced DC maturation on T-cell response, we analyzed the capacity of MUC1 9Tn -DCs and a-MGL-DCs to stimulate the proliferation of allogeneic T cells. Lymphocyte proliferation was evaluated after 5 days of DCs: T cells were cocultured at different ratios, measuring the incorporation of 3 H-thymidine (Fig. 4A) . The results showed that MUC1 9Tn induced a similar T-cell proliferation to that exerted by iDCs. On the other hand, a-MGL-DCs activated a strong T-cell proliferative response, comparable to that induced by mDCs when used at 1:5 and 1:10 ratio. This capacity was significantly higher than those displayed by IgG 1 -DCs, iDCs, and MUC1 9Tn -DCs.
MGL-engaged DCs stimulated IFN-γ production by autologous antigen-specific CD8 + T cells
We finally studied the effect of MGL engagement on the capacity of DCs to activate a CD8 + T-cell mediated antigen-specific response (Fig. 4B ). CD8 + T cells, obtained from three HLAI-A2 + healthy donors, were stimulated with autologous iDCs, mDCs, IgG 1 -DCs, MUC1 9Tn -DCs, and a-MGL-DCs pulsed with HLAI-A2 
restricted Flu peptide (GILGFVFTL). CD8
+ T-cell activation was measured as Interferon (IFN)-γ production in enzyme-linked immunospot (ELISpot) assay. Results indicated that MGL-stimulated DCs, both by MUC1 9Tn and anti-MGL antibody ligands, were optimal APCs able to induce a strong IFN-γ CD8 + T-cell response similarly to mDCs, while the IFN-γ response activated by iDCs was significantly lower.
Discussion
In the last years, the immunological potential of DCs has been proposed as a basic formula for cancer vaccines. Several clinical trials are currently ongoing worldwide to validate the efficacy of this cellular immunotherapy utilizing ex vivo generated DCs pulsed with a variety of TAAs in different formulations such as tumor lysate and peptides [27] . The optimal targeting of DCs to induce specific anticancer immune activation is however still matter of investigation. The targeting of CLRs on DCs has recently acquired a great interest for cancer immunotherapy. Several authors have recently demonstrated that CLR targeting represents an optimal strategy to enhance antigen presentation by DCs, because CLRs are the designed receptors that can recognize endocytose glycans expressed by TAAs released during tumor progression [10, 17, 18] . Different approaches have been proposed to target CLRs in vivo and in vitro, such as antigen coupling to CLR-specific antibody and recombinant glycoproteins [28] .
MGL receptor belongs to the CLR family and it has recently been shown in mouse models that MGL-targeted DCs modulate the immune response. The targeting of MGL expressed by dermal DCs induced a strong HLA class II-restricted T-cell response with a concomitant induction of a potent anti-Tn antibody response following the internalization of MAG:Tn3 glycoimmunogen, containing a viral CD4
+ T-cell epitope [29] . Moreover, MGL enhanced both CD4 + and CD8 + -T lymphocyte activity in TLR independent manner when interacted with Tn-OVA (ovalbumin) antigen [30] . Tn-polyacrylamide polymers conjugated to streptavidin were efficiently internalized through MGL and primed streptavidin-specific CD4 + T cells [31] . Our previous study, conducted in human setting, demonstrated that the overall structure of Tn-carrying molecules internalized by this receptor highly influenced the antigen processing. In fact, recombinant Tnglycoproteins resembling those shed by tumors remained blocked in HLA class II compartment after internalization, while shorter Tn-antigen formulations were processed in HLA class I and II compartments [18] . Since MGL is a strong binder for Tn-carrying molecular structures, such as Tn-TAAs, and is expressed on human DCs during differentiation, we were prompted to further investigate the role of this specific targeting receptor on DC performance, envisaging possible application in cancer vaccines.
We used two different types of ligands: an anti-MGL antibody as a classical model of specific receptor binder and MUC1 9Tn peptide as Tn-carrying TAA that we previously demonstrated to be cross-processed to HLA class I [18] . First, we analyzed DC phenotype changes induced by MGL engagement. The glycopeptide MUC1 9Tn and the antibody were both able to promote similar, although distinct effects on DCs. In fact, MUC1 9Tn -DCs showed a significant upregulation of HLAII-DR, CD83, and CD40 and exhibited a trend in the upregulation of CCR7, CD11c, and CD1a. These phenotypic changes were accompanied by a moderate decrease in endocytosis and an increase in the cell motility. When DCs were treated with the anti-MGL antibody, also a significant increase of CD86 and CCR7 was observed in accordance with a more evident endocytosis downregulation and an increment of antigen presenting activity. The effects of the C-type lectin targeting on DCs have been largely investigated by several authors using specific antibodies or antigenconjugated MoAb. Dectin-1 engagement promoted an increase in the expression of CD86, CD80, CD40, and HLAII-DR [32] , while DC-SIGN ligation did not stimulate DC maturation [33] . In other studies, C-type lectin activation resulted in the secretion of multiple cytokines and chemokines by DCs [32, 34, 35] , even if the upregulation of costimulatory molecules was not always detected. Moreover, C-type lectin targeting increased DC cross-presentation or improved the activation by DCs of specific lymphocyte subsets [36, 37] .
In our system the engagement of MGL by both ligands induced activation of antigen-specific CD8 + T cells as detected by IFN-γ production, while only DCs stimulated with the antibody, induced the proliferation of allogeneic T cells similarly to mDCs. The difference in the profile of costimulatory molecules observed could make account for the distinct immunogenicity. In fact, CD86, that strongly contributes to alloreaction [38] , was upregulated only in a-MGL-DCs and not in MUC 9Tn -DCs, while upregulation of CD40 was induced by both ligands. The balancing among the expression profile of costimulatory molecules, inhibitory regulators, and the timing of expression on DCs finely tunes the interaction between APCs and the effector T cells. In addition, this DC population was able to switch the balance IL-12/IL-10. In fact, the increase of IL-12 production compared with IL-10 in this DC subset further suggests their capacity to favor a polarization toward a Th1 population. The shaping of phenotypic and functional performance of DCs after C-type lectin engagement strongly correlates to the triggering of intracellular signaling [4] .
We have demonstrated for the first time that MGL oligomerized and triggered the phosphorylation of ERK1,2 and the activation of NF-κB signal. The MUC1 9Tn glycoimmunogen and the antibody showed the same ability to induce clusters and to activate the p50 transcription factor, but they acted differently in the triggering of ERK1,2 pathway (stronger activation in MUC1 9Tn -DCs). It is well known that ERK1,2 pathway profoundly influences DC activity. The effects of ERK1,2 signaling on maturation of DCs are highly variable and dependent on the type of stimulus added to the cells, even if it appears to negatively regulate the phenotypic and functional maturation of DCs [39] . On the other hand, the activation of NF-κB signal is essential for DC development and survival and has a high impact on DC maturation and in the production of proinflammatory cytokines, such as IL-12, IL-6, TNF-α, and IFN-α/β [23, 40] . In our system, two different ligands for the same receptor induced a distinct dynamic and intensity of the ERK1,2 activation and this could make account of the distinct phenotypic and functional performances displayed by MUC1 9Tn -DCs versus a-MGL-DCs. The choice of the binder for DCs targeting is a crucial step when designing DC cancer vaccines.
CLR-specific antibodies coupled with TAAs have been proposed for the targeting of DCs. However, the efficiency of these binders could be severely hampered by reduced tissue penetration and nonspecific Fc Receptor (FcR)-mediated uptake by other cells. The use of synthetic Tn-TAAs for DC targeting represents a promising approach and our model of glycopeptide, MUC1 9Tn , represents here the "proof of concept" of this strategy. We believe and speculate that modifying Tn-density, the length and steric structure of the Tn-peptide, we can possibly obtain immunogens that can efficiently bind to MGL, strongly activate DCs, mimic the effects of a danger signal, and achieve an efficient presentation in HLA class I and II pathways as previously described [18] . Moreover, a wide variety of immunogens carrying Tn-epitopes could be envisaged, where the Tn-peptide stretch could only be a way to deliver other TAAs as well as other molecules.
It is also important to retain that the molecular targeting as well as the choice of the antigen represent only "one side of the coin" in designing cancer vaccines. The choice of the optimal DC subset for priming T cells combined to strategies to contain or eliminate immunosuppression are crucial parameters that should be considered to obtain an efficacious and long-lasting anticancer immunoresponse [41] .
In conclusion, in this work we have demonstrated that MGL engagement promotes DC activation and that the effects of this activation are strongly dependent on the type of stimulus added to the cells. The high plasticity of MGL and its capacity to modulate the immune response combined to its ability to endocyte and process GalNAc-carrying antigens makes MGL an optimal candidate to be targeted for immunotherapy.
Materials and methods
DC generation
Peripheral blood mononuclear cells were isolated by FicollHypaque gradient (1077 g/mL; Pharmacia LKB, Uppsala, Sweden). Monocytes (CD14 + ) were purified by CD14 MicroBeads (Miltenyi Biotech, Paris, France) and cultured (5 × 10 5 cells/mL) in RPMI 1640 (Hyclone, UT, USA) supplemented with 2 mM L-glutamine (Sigma Chemical Company, St. Louis, MO, USA), penicillin 100 U/mL (Sigma), streptomycin 100 μg/mL (Sigma) with 10% heat-inactivated Fetal Calf Serum (Hyclone). A total of 50 ng/mL rhGranulocyte-Macrophage colony-stimulating factor (R&D System, Minneapolis, MN) and 1000 U/mL rhIL-4 (R&D System) were added at day 0. iDCs were collected at day 5 and matured with rhIL-1β (10 ng/mL), IL-6 (10 ng/mL), TNF-α (10 ng/mL), and prostaglandin E2 (1 μg/mL) (all purchased by R&D System) for 16 h. At day 6 DCs were considered matured.
Chemoenzymatic synthesis of glycopeptides
Unglycosylated MUC1-60-mer peptide (VTSAPDTRPAPGST APPAHG) n = 3 representing 3TRs was synthesized by Neosystem, Prague, Czech Republic) as described by Fontenot et al. [42] . Recombinant human polypeptide GalNAc-transferase GalNAc-T2, was used to direct GalNAc O-glycosylation of MUC1 peptides at three sites per TR (MUC1 9Tn ) as previously described [43] . Glycosylation was controlled using nanoscale reversed-phase columns (Poros R3, PerSeptive Biosystems, Framingham, MA, USA) and MALDI-TOF mass spectrometry.
Flow cytometry
Cell phenotype staining was performed using the following anti- 
Confocal microscopy
To study the MGL distribution on DC plasma membrane, iDCs (1 × 10 6 /sample) were fixed with 4% paraformaldehyde (Electrom Microscopy Science, Hatfield, PA, USA) for 30 min, followed by glycine 0.1 M (Sigma-Aldrich, San Luis, USA) for 10 min and 0.1% Triton-X-100 (Bio-Rad Laboratories, CA, USA) for 4 min. iDCs were incubated with MoAb anti-MGL (Dendritics) for 45 min, and then with goat anti-mouse-FITC F(ab') 2 antibody. Cells were added on to SuperFrost R PlusMicroscope Slides (MenzelGlaser, Germany) after the addition of Mowiol mounting medium (Calbiochem, Darmstadt, Germany). To visualize the MGL distribution after the receptor engagement, iDCs were treated with MUC1 9Tn glycopeptide and next incubated with MoAb anti-MGL (Dendritics) followed by goat anti-mouse-FITC F(ab') 2 antibody. Cells were then fixed and scanned in a series of 0.5-μm sequential sections with an ApoTome System (Zeiss, Ober Kochen, Germany) connected with an Axiovert 200 inverted microscope (Zeiss); image analysis was then performed by the Axiovision software (Zeiss), and a three-dimensional reconstruction was obtained.
MGL oligomerization and immunoprecipitation
A total of 5 × 
Western blotting
For oligomerization studies, immunoprecipitated samples were subjected to 3-8% or 4-12% sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and the resolved proteins were transferred electrophoretically to nitrocellulose transfer membrane (Schleicher and Schuell, Dassel, Germany). The unspecific sites were blocked with phosphate-buffered saline + 5% bovine serum albumin (BSA) (Sigma) overnight at 4 • C.
Nitrocellulose membrane was then incubated with MoAb anti-MGL (Dendritics) (1:10) overnight at 4
• C followed by peroxidaseconjugated goat anti-mouse IgG (H + L) antibody (1:20,000) (Jackson ImmunoResearch Laboratories, Suffolk, UK) 1 h at RT. For the signal transduction experiments, iDCs were stimulated with MUC1 9Tn peptide or with anti-MGL (Dendritics) and IgG 1 antibodies as described above. Cells were washed and incubated at 37
• C from 5 to 120 min. DCs were then lysed using the 
DC migration
DC migration toward CCL19 (MIP-3β/CCL19 C/F, (R&D Systems) was determined using chemotaxis assay performed in 24-well Transwell cell culture chambers (Corning Costar Corp., NY, USA) containing a 5.0 μm-pore size membrane. The upper chamber was loaded with 1 × 10 5 iDCs, mDCs, IgG 1 -DCs, a-MGL-DCs, and MUC1 9Tn -DCs. The lower compartment contained 600 μL RPMI 1640 medium, 0.5% BSA (Sigma) and 10 mM N-2-hydroxyethylpiperazine-N -2-ethanesulfonic acid (Hyclone) with CCL19 (250 ng/mL). After incubation at 37
• C for 90 min, cells that had migrated into the lower compartment were collected and the percentage of migration was determined as migrated/total events using FACSCalibur flow cytometer (Becton Dickinson).
DC cytokine production
iDCs, mDCs, IgG 1 -DCs, a-MGL-DCs, and MUC1 9Tn -DCs were stimulated with phorbol myristate acetate (25 ng/mL) (Sigma) and ionomicyn (250 ng/mL) (Sigma) in presence of Brefeldin A (10μg/mL) for 16 h at 37
• C. Cells were collected, fixed, and permeabilized with Saponin (Sigma) solution at 0.5%. Intracellular staining was carried out using anti-IL-10-FITC (R&D System) and anti-IL-12-FITC (R&D System) antibodies. Cells were acquired by FACSCanto flow cytometer and analyzed by FACSDiva software.
Mix lymphocyte reaction
Naïve CD4 + T cells were purified from peripheral blood by FicollHypaque gradient (1077 g/mL; Pharmacia LKB) followed by CD4 and CD45RA immunomagnetic isolation (Miltenyi Biotech cells/well) were plated in triplicate with iDCs, mDCs, IgG 1 -DCs, a-MGL-DCs, and MUC1 9Tn -DCs with HLAI-A2 restricted Flu peptide (GILGFVFTL) (10 μg/mL) (Proimmune, Oxford, UK) for 16 h at 37 • C. Cells were then removed and after washing, cytokine release was detected with biotinylated anti-IFN-γ antibody (Pharmingen) (5 μg/mL, 50 μL/well, 2 h at RT) revealed with streptavidin-alkaline phosphatase (Pharmingen) (dilution 1:2000, 50 μL/well, 2 h at RT) and chromogen substrate (5-bromo-4-chloro-3-indolylphosphate (BCIP)/nitroblue tetrazolium alkaline phosphatase substrate, Sigma) (50 μL/well). Spots were counted using the ImmunoSpot Image Analyzer (Aelvis, Germany).
Statistical analysis
Descriptive statistics (average and standard deviation) were used to describe the various groups of data. Student's paired ttest was used to analyze statistical differences between groups. Significance is indicated when the p value is less than 0.05.
